<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="is being missed. Indeed, for many other viral infections, early" exact="treatment" post="soon after development of symptoms is associated with decreased"/>
 <result pre="in clinical trials treating SARS Co-V-2 early during infection. Early" exact="treatment" post="of SARS-CoV-2 could disproportionately lower the mortality rate, but"/>
 <result pre="effect on the elderly [1â€&quot;3]. The only policy option is" exact="physical distancing" post="to â€œflatten the curveâ€� and decrease incident cases [4]."/>
 <result pre="wave will be a difficult balancing act. Full relaxation of" exact="physical distancing" post="will allow a rapid surge of severe acute respiratory"/>
 <result pre="To manage the pandemic, effective strategies are needed to treat" exact="infection" post="and lower its fatality rate. To this end, the"/>
 <result pre="CoV-2 provides a golden opportunity to diagnose and treat, before" exact="infection" post="becomes uncontrollable. The average time between development of symptoms"/>
 <result pre="is 14â€&quot;21 days [7]. Viral kinetic studies demonstrate that early" exact="infection" post="consists of a 2- to 3-day surge in viral"/>
 <result pre="Figure 1. Schematic of severe acute respiratory syndrome coronavirus 2" exact="infection" post="in a symptomatic person. RNA, ribonucleic acid. Symptoms often"/>
 <result pre="10â€…000 cases rather than 10, managing a SARS CoV-2 lung" exact="infection" post="is more difficult when the entire tissue is overrun"/>
 <result pre="a small portion. There is a longstanding precedent that early" exact="treatment" post="of viruses leads to better outcomes. In a trial"/>
 <result pre="the likelihood that interventions would be lifesaving [12]. Early influenza" exact="treatment" post="causes shorter duration of shedding and symptoms [13]. For"/>
 <result pre="shedding and symptoms [13]. For human immunodeficiency virus (HIV), early" exact="treatment" post="confers mortality benefits and lowers community transmission [14, 15]."/>
 <result pre="persist for weeks leading to multiple lost workdays [17]. Early" exact="treatment" post="could provide benefit to those not at risk for"/>
 <result pre="benefit to those not at risk for hospitalization. Widespread early" exact="treatment" post="could also mitigate local epidemics. Although a proportion of"/>
 <result pre="that must be solved. First, to implement a scalable early" exact="treatment" post="strategy, widely available testing is needed. Home testing with"/>
 <result pre="First, to implement a scalable early treatment strategy, widely available" exact="testing" post="is needed. Home testing with self-sampling allows rapid diagnosis"/>
 <result pre="scalable early treatment strategy, widely available testing is needed. Home" exact="testing" post="with self-sampling allows rapid diagnosis within 1 day of"/>
 <result pre="available testing is needed. Home testing with self-sampling allows rapid" exact="diagnosis" post="within 1 day of developing symptoms and avoids the"/>
 <result pre="this available to citizens in cities with high burden of" exact="infection" post="[24]. Self-quarantine will be more likely if people know"/>
 <result pre="progression to severe disease. Virologic endpoints are established surrogates of" exact="treatment" post="efficacy for HIV, hepatitis B, hepatitis C, HSV-2, influenza,"/>
 <result pre="that a profound reduction in shedding early during SARS Co-V-2" exact="infection" post="will translate into prevention of oxygen need and hospitalization."/>
 <result pre="a 30-participant trial with blinded and equally sized placebo and" exact="treatment" post="arms would have 80% power to detect a 5-day"/>
 <result pre="be rapidly screened. We propose urgent double-blind, placebo-controlled, clinical trials" exact="testing" post="agents with biologic activity against SARS CoV-2 in outpatients."/>
 <result pre="studies in humans, including remdesivir, favipiravir, and selinexor [29]. Drug" exact="screening" post="revealed many other US Food and Druge Administration licensed"/>
 <result pre="study recently pioneered home delivery of baloxavir for early influenza" exact="treatment" post="in a clinical trial [31]. Alternatively, a specialized clinic"/>
 <result pre="J Med2016; 375:830â€&quot;9.27424812 21.FryAM, GoswamiD, NaharK, et al.Effects of oseltamivir" exact="treatment" post="of index patients with influenza on secondary household illness"/>
</results>
